On Nov 01, major Wall Street analysts update their ratings for $Biogen (BIIB.US)$, with price targets ranging from $190 to $302.
Morgan Stanley analyst Terence Flynn downgrades to a hold rating, and adjusts the target price from $285 to $204.
BofA Securities analyst Jason Zemansky initiates coverage with a hold rating, and sets the target price at $250.
Wells Fargo analyst Mohit Bansal maintains with a hold rating, and adjusts the target price from $225 to $190.
Jefferies analyst Michael Yee maintains with a buy rating, and maintains the target price at $250.
TD Cowen analyst Phil Nadeau maintains with a buy rating, and maintains the target price at $275.
Furthermore, according to the comprehensive report, the opinions of $Biogen (BIIB.US)$'s main analysts recently are as follows:
The company's recent product launches continue to face challenges amidst a backdrop of intensifying competition. Furthermore, significant developments from the company's emerging pipeline appear to be projected for 2026 and later.
The launch of Leqembi has not met expectations, and there appears to be a limited range of pipeline opportunities in the coming year. The analyst acknowledges a prior underestimation of the initial reimbursement and logistical challenges faced by Leqembi. A balanced risk/reward perspective is now seen for Biogen, with a cautious projection for lecanemab's progress.
Biogen's third-quarter financial performance was robust, with total revenues of $2.47 billion surpassing estimates of $2.38 billion and consensus of $2.43 billion, while adjusted earnings per share of $4.08 exceeded the anticipated $3.75 and consensus of $3.77. The sales trajectory of Leqembi is seen to be exceeding consensus, indicating a vigorous build-up of infrastructure. It is expected that the intravenous maintenance and subcutaneous forms will considerably enhance adoption in the year 2025.
Biogen's Q3 revenue met expectations while EPS surpassed projections. The company also increased its EPS guidance for 2024. The launch of Leqembi is gathering pace, although logistical and capacity constraints are still impeding wider adoption.
Here are the latest investment ratings and price targets for $Biogen (BIIB.US)$ from 11 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月1日，多家華爾街大行更新了$渤健公司 (BIIB.US)$的評級，目標價介於190美元至302美元。
摩根士丹利分析師Terence Flynn下調至持有評級，並將目標價從285美元下調至204美元。
美銀證券分析師Jason Zemansky首次給予持有評級，目標價250美元。
富國集團分析師Mohit Bansal維持持有評級，並將目標價從225美元下調至190美元。
富瑞集團分析師Michael Yee維持買入評級，維持目標價250美元。
TD Cowen分析師Phil Nadeau維持買入評級，維持目標價275美元。
此外，綜合報道，$渤健公司 (BIIB.US)$近期主要分析師觀點如下：
該公司最近的產品推出在日益激烈的競爭背景下繼續面臨挑戰。此外，該公司新興管線中的重大發展似乎計劃安排在2026年及以後。
Leqembi的推出未達預期，未來一年似乎僅有有限的管線機會。分析師承認之前低估了Leqembi面臨的最初報銷和後勤挑戰。現在對於渤健公司，風險/回報觀點更加平衡，對lecanemab的進展持謹慎態度。
渤健公司第三季度財務表現強勁，總收入達到了$24.7億，超過了$23.8億的預期和$24.3億的共識，調整後的每股收益爲$4.08，超過了預期的$3.75和共識的$3.77。Leqembi的銷售軌跡被認爲超過了共識，表明製造行業的建設正在積極推進。預計靜脈維護和皮下給藥形式將極大增強其在2025年的採用。
渤健公司第三季度營業收入符合預期，而每股收益超過了預測。公司還提高了2024年的每股收益指引。Leqembi的推出正逐漸加快，儘管後勤和產能約束仍在阻礙更廣泛的採用。
以下爲今日11位分析師對$渤健公司 (BIIB.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
